TNFSF8 (PRA-052 Biosimilar) Recombinant Monoclonal Antibody

Code: CSB-RA023996MB1HU

Rate （N/A）
Review （0）

Size:

100ug

100ug500ug1mg5mg10mg50mg100mg200mg

US$199

Quantity:

Species Reactivity: Human

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

P32971

Alternative Names

MK8690 research-grade biosimilar; MK-8690 research-grade biosimilar; PR600 research-grade biosimilar; PR-600 research-grade biosimilar; PRA052 research-grade biosimilar ;TNFSF8 antibody; CD30L antibody; CD30LG antibody; Tumor necrosis factor ligand superfamily member 8 antibody; CD30 ligand antibody; CD30-L antibody; CD antigen CD153 antibody

Species Reactivity

Human

Immunogen

Recombinant Human TNFSF8 protein

Conjugate

Non-conjugated

Clonality

Monoclonal

Buffer

0.01M PBS，pH7.4

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Notes

Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.

Lead Time

3-4 weeks
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Concentration

It differs from different batches. Please contact us to confirm it.

Usage

It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Datasheet & COA

Antibody FAQs

Description

This recombinant monoclonal antibody is developed as a research-grade biosimilar to PRA-052, targeting TNFSF8 (tumor necrosis factor superfamily member 8), also known as CD30 ligand or CD153. TNFSF8 is a type II transmembrane glycoprotein primarily expressed on activated T cells, macrophages, and certain dendritic cells. It binds to CD30 (TNFRSF8) and plays critical roles in immune regulation, including T cell activation, cytokine production, and inflammatory responses. TNFSF8/CD30 interactions are particularly significant in the pathogenesis of lymphoproliferative disorders, Hodgkin lymphoma, and anaplastic large cell lymphoma, where aberrant CD30 signaling contributes to malignant transformation and disease progression. This pathway is also implicated in autoimmune conditions and transplant rejection.

As a biosimilar to the reference antibody PRA-052, this product provides researchers with a reliable tool for investigating TNFSF8 biology, CD30-CD30L signaling mechanisms, and their roles in immune-mediated diseases and hematologic malignancies. It supports studies exploring therapeutic targeting strategies and biomarker development in oncology and immunology research.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

Cytokine that binds to TNFRSF8/CD30. Induces proliferation of T-cells.

Gene References into Functions

circulant sCD30L is functionally active and that it may favor persistence of active inflammation by inducing apoptosis of CD30(+)T cells, known to down-modulate inflammation in rheumatoid synovitis. PMID:24447865
TNFSF8 is an important leprosy T1R susceptibility gene. PMID:25320285
The heritability of IgA levels is moderate and can partly be attributable to common variation in the CD30L locus. PMID:24676358
The TNFSF8 polymorphisms rs927374 and rs2295800 were associated with neutrophil count. This finding suggests that post-MI inflammatory response is genetically modulated. PMID:22033252
Positional candidate gene screening in the SPA2 locus allowed us to identify and replicate an association between a rare SNP located in TNFSF8 and spondylarthritis. PMID:21480186
a possible role of novel TNFSF8 variants in susceptibility to lung cancer. PMID:21292647
capability to up-regulate expression of CD30, release of soluble CD30 and production of IL-4 in pre-activated T cells upon co-culture PMID:11728464
Mast cells were found to be the predominant CD30 ligand-positive (CD30L-positive) cell in the chronic inflammatory skin diseases psoriasis and atopic dermatitis. PMID:16964309
CD153 antigen was expressed by synovial mast cells, and correlated with serum levels, in Rheumatoid Arthritis patients PMID:19208589
Single nucleotide polymorphism in TNFSF8 gene is associated with bone disease in myeloma. PMID:19657367